HOW HAS AUTHORISATION AFFECTED SUBSTITUTION: RESULTS OF THE STUDY ON THE IMPACTS OF AUTHORISATION

Stock-taking conference on the implementation of REACH authorisation

14th November 2017

Presentation by Rohit Mistry (eftec)









SUBSTITUTION AWAY FROM SVHC'S


Evidence of substitution

Efforts to substitute


Summary

SVHCs substituted the most


EVIDENCE OF SUBTITUTION



TIME TAKEN TO SUBSTITUTE




AUTHORISATION STAGE THAT TRIGGERED SUBSTITUTION ACTIVITY




- Screening of substance and Risk Management Option Analysis (RMOA)
- Inclusion of substance in Candidate List
- Recommendation for inclusion of substance in Authorisation List (Annex XIV)
- Inclusion of substances in Annex XIV
- Applications for authorisation (AfA)
- Post-authorisation decisions (e.g. after sunset date of Annex XIV substance)

EVIDENCE OF SUBSTITUTION RELATED ACTIVITIES


Most frequent SVHCs mentioned




TYPES OF ACTIVITIES BEING CARRIED OUT




DRIVERS FOR SUBSTITUTION RELATED ACTIVITIES



REASONS FOR A LACK OF SUBSTITUTION RELATED ACTIVITIES



APPLICANTS - FUTURE POSSIBILITIES TO SUBSTITUTE



WHAT IS IN THE STUDY ABOUT SUBSTITUTION

Review of existing literature

Online survey results

Case studies

Details of R&D plans within AfA's

SUMMARY

Clear evidence of substitution away from SVHCs

2 Substitution is not limited to only a few SVHCs

3 Substitution not limited to just those on Annex XIV

Substitution away from SVHCs expected to continue over time

REACH authorisation process is a key driver for substitution of SVHCs

Technical feasibility / lack of alternatives worth testing are the main barriers to more substitution

CONTACT

Rohit Mistry

rohit@eftec.co.uk

Tel: +44(0)207 580 5383

www.eftec.co.uk

eftec